Share price
4D pharma to complete enrolment of combination trials in Q4; expects results from pancreatic cancer in 2021
3 February 2021 | 09:48am
StockMarketWire.com - Pharmaceutical company 4D pharma said it expected to complete enrolment for 'Part B' of the clinical trial assessing its lead cancer drug MRx0518 combined with Keytruda in the fourth quarter and receive initial results from its pancreatic cancer trial later this year.
Part A of the study included an initial safety phase assessing dose, while the part B cohort expansion phase assessed clinical benefit in addition to safety.
The company said 24 additional patients across five active US sites had now been treated in part B of this ongoing study, with target tumor reductions having been observed at the nine weeks.